Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the 'Company'), a biopharmaceutical company specializing
WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. , a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2023."I am pleased to announce 2023 was a record year for revenues," said Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera.
Total operating expenses were $14.5 million for the fourth quarter of 2023 compared with $15.8 million for the fourth quarter of 2022. Cost of revenues was $5.4 million for the fourth quarter of 2023 compared with $5.3 million for the prior-year quarter, driven by higher Ameluz product revenue. Selling, general and administrative expenses were $9.1 million for the fourth quarter of 2023 compared with $10.
Total revenues for 2023 were $34.1 million compared with $28.7 million for 2022, an increase of approximately 19%, primarily driven by a higher volume of Ameluz sales and a higher average Ameluz selling price.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update(This release corrects the release that was posted earlier on March 15, 2024 to update the Consolidated Balance Sheets)Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN
Read more »
Ainos, Inc.: Ainos Reports Full Year 2023 Financial ResultsStrategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024Advancing VELDONA drug candidates to Phase III clinical studiesExpanding market of AI Nose-powered VOC-sensing technology
Read more »
AIXTRON SE Buy (Jefferies & Company Inc.) 09.03.2024 | AnalyseAIXTRON SE Buy (Jefferies & Company Inc.) 09.03.2024 | Analyse | finanzen.net
Read more »
TeamViewer Buy (Goldman Sachs Group Inc.) 05.03.2024 | AnalyseTeamViewer Buy (Goldman Sachs Group Inc.) 05.03.2024 | Analyse | finanzen.net
Read more »
AstraLabs Inc.: AstraAI: Redefining Innovation with the Ultimate AI Ecosystem in BlockchainDUBAI, UAE / ACCESSWIRE / February 24, 2024 / In a mere 100 days since its launch, AstraAI has not only demonstrated its prowess in the cryptocurrency market but has also established itself as a beacon
Read more »
Buy für Allianz-Aktie nach Jefferies & Company Inc.-AnalyseJefferies & Company Inc. hat eine umfassende Prüfung der Allianz-Aktie durchgeführt. Hier sind die festgestellten Resultate.
Read more »